Company profile
Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07764146 | phase1 | recruiting | 2026-09-03 | 2029-04-28 | Voyager Therapeutics | An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease |
| NCT04885114 | phase1 | withdrawn | 2021-07-30 | 2024-12-30 | Voyager Therapeutics | Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease |
| NCT06874621 | phase1_2 | active_not_recruiting | 2025-03-03 | 2027-05-01 | Voyager Therapeutics | VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease |
FDA applications (0)
No records yet.